142 related articles for article (PubMed ID: 8774480)
1. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
De Vries TJ; De Wit PE; Clemmensen I; Verspaget HW; Weidle UH; Bröcker EB; Ruiter DJ; Van Muijen GN
J Pathol; 1996 Jul; 179(3):260-5. PubMed ID: 8774480
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
3. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
4. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
5. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
de Vries TJ; Verheijen JH; de Bart AC; Weidle UH; Ruiter DJ; van Muijen GN
Cancer Res; 1996 Mar; 56(6):1432-9. PubMed ID: 8640836
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
9. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
10. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation in melanocytic neoplasia.
Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
13. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
14. High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ
Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S
Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459
[TBL] [Abstract][Full Text] [Related]
17. Cadherin expression in melanocytic naevi and malignant melanomas.
Cowley GP; Smith ME
J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
19. Expression of neurotrophins and their receptors in pigment cell lesions of the skin.
Innominato PF; Libbrecht L; van den Oord JJ
J Pathol; 2001 May; 194(1):95-100. PubMed ID: 11329147
[TBL] [Abstract][Full Text] [Related]
20. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
